DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,487,500 | +3.1% | 10,026 | -0.2% | 0.28% | +4.1% |
| Q2 2023 | $2,411,762 | -10.5% | 10,049 | -6.0% | 0.27% | -15.6% |
| Q1 2023 | $2,693,404 | -1.4% | 10,686 | +3.8% | 0.32% | -6.4% |
| Q4 2022 | $2,732,863 | +13.4% | 10,296 | +10.3% | 0.34% | +3.6% |
| Q3 2022 | $2,410,000 | +6.5% | 9,332 | +4.6% | 0.33% | +9.6% |
| Q2 2022 | $2,262,000 | -10.7% | 8,921 | +3.3% | 0.30% | -0.7% |
| Q1 2022 | $2,534,000 | -7.0% | 8,638 | +4.3% | 0.30% | -6.8% |
| Q4 2021 | $2,724,000 | +9.0% | 8,278 | +0.8% | 0.32% | +2.2% |
| Q3 2021 | $2,500,000 | +22.7% | 8,211 | +8.2% | 0.32% | +18.2% |
| Q2 2021 | $2,037,000 | +26.1% | 7,589 | +5.8% | 0.27% | +13.0% |
| Q1 2021 | $1,615,000 | +1.4% | 7,174 | +0.0% | 0.24% | -5.2% |
| Q4 2020 | $1,593,000 | -8.0% | 7,173 | -10.8% | 0.25% | -17.4% |
| Q3 2020 | $1,731,000 | +19.2% | 8,037 | -2.1% | 0.30% | +12.2% |
| Q2 2020 | $1,452,000 | +25.0% | 8,211 | -2.2% | 0.27% | +8.4% |
| Q1 2020 | $1,162,000 | -14.7% | 8,398 | -5.4% | 0.25% | +0.8% |
| Q4 2019 | $1,362,000 | +5.9% | 8,876 | -0.3% | 0.25% | -2.4% |
| Q3 2019 | $1,286,000 | +1.6% | 8,901 | +0.5% | 0.25% | -1.2% |
| Q2 2019 | $1,266,000 | +11.3% | 8,855 | +2.8% | 0.26% | -11.4% |
| Q1 2019 | $1,137,000 | +29.1% | 8,611 | +0.8% | 0.29% | +20.3% |
| Q4 2018 | $881,000 | +70.1% | 8,542 | +79.2% | 0.24% | +74.6% |
| Q3 2018 | $518,000 | +10.2% | 4,768 | +0.0% | 0.14% | +1.5% |
| Q2 2018 | $470,000 | +10.1% | 4,767 | +7.2% | 0.14% | +6.2% |
| Q1 2018 | $427,000 | +16.3% | 4,448 | +15.5% | 0.13% | +7.6% |
| Q4 2017 | $367,000 | +16.1% | 3,851 | +6.1% | 0.12% | +11.2% |
| Q3 2017 | $316,000 | +3.9% | 3,629 | -1.4% | 0.11% | -9.3% |
| Q2 2017 | $304,000 | -3.5% | 3,679 | +0.2% | 0.12% | -26.7% |
| Q1 2017 | $315,000 | +26.0% | 3,673 | +19.5% | 0.16% | +5.2% |
| Q4 2016 | $250,000 | -12.3% | 3,073 | -16.3% | 0.15% | +13.3% |
| Q3 2016 | $285,000 | -3.7% | 3,673 | 0.0% | 0.14% | -8.8% |
| Q2 2016 | $296,000 | – | 3,673 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |